Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope
To further investigate mechanisms of protective immunity that are induced by live, attenuated simian immunodeficiency virus (SIV), three macaques were infected with SIVmacGX2, a nef-disrupted molecular clone. In two of these animals, which expressed the MamuA*01 major histocompatibility complex class I allele, loss of functional activity against an SIV-Gag-encoded immunodominant cytotoxic T lymphocyte (CTL) epitope was observed following prolonged infection. Nonetheless, all three animals were resistant to challenge with an uncloned pool of wild-type SIVmac, whereas four naïve controls became infected. Tetramer staining revealed the rapid generation of CD8+ T-cell responses against gag- and tat-encoded immunodominant epitopes in MamuA*01+ challenge controls. The dynamics of these T-cell responses to the wild-type virus were similar to those observed following primary infection of the vaccine group with attenuated virus. In contrast, neither tetramer staining nor gamma interferon ELISpot assay revealed an immediate, systemic, anamnestic response in the wild-type-challenged, attenuated SIV-infected animals. Functional CTL capacity had not been lost in this group, as lytic activity was still evident 17 weeks after challenge. Both attenuated and wild-type viruses induced a disseminated CD8+ T-cell response, which was of a higher magnitude in lymphoid tissues than in the periphery. These results suggest that, at least as measured in the periphery, protection against wild-type infection that is induced by live, attenuated SIV is not dependent on a rechallenge-driven expansion of immunodominant epitope-specific CD8+ T cells and, therefore, pre-existing activity may be sufficient to prevent superinfection.
AllenT. M.,
SidneyJ.,
del GuercioM.-F.8 other authors1998; Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol 160:6062–6071
AllenT. M.,
O'ConnorD. H.,
JingP.16 other authors2000; Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386–390[CrossRef]
AllenT. M.,
MothéB. R.,
SidneyJ.11 other authors2001; CD8+ lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule MamuA*01: implications for vaccine design and testing. J Virol 75:738–749[CrossRef]
AlmondN.,
RoseJ.,
SangsterR.,
SilveraP.,
StebbingsR.,
WalkerB.,
StottE. J.1997; Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol 78:1919–1922
ArnoldC.,
JenkinsA.,
AlmondN.,
StottE. J.,
KentK. A.1999; Monoclonal antibodies recognize at least five epitopes on the SIV Nef protein and identify an in vitro-induced mutation. AIDS Res Hum Retrovir 15:1087–1097[CrossRef]
BabaT. W.,
LiskaV.,
KhimaniA. H.8 other authors1999; Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5:194–203[CrossRef]
BogersW. M. J. M.,
NiphuisH.,
ten HaaftP.,
LamanJ. D.,
KoornstraW.,
HeeneyJ. L.1995; Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS 9:F13–F18
BorrowP.,
LewickiH.,
HahnB. H.,
ShawG. M.,
OldstoneM. B. A.1994; Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103–6110
ClarkeS.,
AlmondN.,
BerryN.2003; Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. Virology 306:100–108[CrossRef]
ConnorR. I.,
MontefioriD. C.,
BinleyJ. M.8 other authors1998; Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 72:7501–7509
CranageM. P.,
WhatmoreA. M.,
SharpeS. A.7 other authors1997; Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229:143–154[CrossRef]
CranageM. P.,
SharpeS. A.,
WhatmoreA. M.,
PolyanskayaN.,
NorleyS.,
CookN.,
LeechS.,
DennisM. J.,
HallG. A.1998; In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose. J Gen Virol 79:1935–1944
DanielM. D.,
KirchhoffF.,
CzajakS. C.,
SehgalP. K.,
DesrosiersR. C.1992; Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1941[CrossRef]
FlynnK. J.,
RiberdyJ. M.,
ChristensenJ. P.,
AltmanJ. D.,
DohertyP. C.1999; In vivo proliferation of naïve and memory influenza-specific CD8+ T cells. Proc Natl Acad Sci U S A 96:8597–8602[CrossRef]
GerettiA.-M.,
HulskotteE. G. J.,
DingsM. E. M.,
van BaalenC. A.,
van AmerongenG.,
NorleyS. G.,
BoersP.,
GrutersR.,
OsterhausA. D. M. E.1999; Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5. J Infect Dis 180:1133–1141[CrossRef]
Hofmann-LehmannR.,
VlasakJ.,
WilliamsA. L.,
ChenineA.-L.,
McClureH. M.,
AndersonD. C.,
O'NeilS.,
RuprechtR. M.2003; Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17:157–166[CrossRef]
KostenseS.,
OggG. S.,
MantingE. H.8 other authors2001; High viral burden in the presence of major HIV-specific CD8+ T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 31:677–686[CrossRef]
KoupR. A.,
SafritJ. T.,
CaoY.,
AndrewsC. A.,
McLeodG.,
BorkowskyW.,
FarthingC.,
HoD. D.1994; Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650–4655
KurodaM. J.,
SchmitzJ. E.,
SethA.8 other authors2000; Simian immunodeficiency virus-specific cytotoxic T lymphocytes and cell-associated viral RNA levels in distinct lymphoid compartments of SIVmac-infected rhesus monkeys. Blood 96:1474–1479
McKayP. F.,
SchmitzJ. E.,
BarouchD. H.,
KurodaM. J.,
LiftonM. A.,
NickersonC. E.,
GorgoneD. A.,
LetvinN. L.2002; Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys. J Immunol 168:332–337[CrossRef]
MetznerK. J.,
JinX.,
LeeF. V.8 other authors2000; Effects of in vivo CD8+ T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med 191:1921–1931[CrossRef]
NilssonC.,
MäkitaloB.,
ThorstenssonR.,
NorleyS.,
Binninger-SchinzelD.,
CranageM.,
RudE.,
BiberfeldG.,
PutkonenP.1998; Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12:2261–2270[CrossRef]
NixonD. F.,
DonahoeS. M.,
KakimotoW. M.,
SamuelR. V.,
MetznerK. J.,
GettieA.,
HankeT.,
MarxP. A.,
ConnorR. I.2000; Simian immunodeficiency virus-specfic cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine. Virology 266:203–210[CrossRef]
NorleyS.,
BeerB.,
Binninger-SchinzelD.,
CosmaC.,
KurthR.1996; Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219:195–205[CrossRef]
PolyanskayaN.,
SharpeS.,
CookN.,
LeechS.,
BanksJ.,
DennisM.,
HallG.,
StottJ.,
CranageM.1997; Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res Hum Retrovir 13:923–931[CrossRef]
SawaiE. T.,
HamzaM. S.,
YeM.,
ShawK. E.,
LuciwP. A.2000; Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J Virol 74:2038–2045[CrossRef]
SharpeS. A.,
WhatmoreA. M.,
HallG. A.,
CranageM. P.1997; Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus. J Gen Virol 78:1923–1927
StebbingsR.,
StottJ.,
AlmondN.10 other authors1998; Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum Retrovir 14:1187–1198[CrossRef]
StebbingsR. J.,
AlmondN. M.,
StottE. J.9 other authors2002; Mechanisms of protection induced by attenuated simian immunodeficiency virus. V No evidence for lymphocyte-regulated cytokine responses upon rechallenge. Virology 296:338–353[CrossRef]
Ten HaaftP.,
VerstrepenB.,
ÜberlaK.,
RosenwirthB.,
HeeneyJ.1998; A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 72:10281–10285
WhatmoreA. M.,
CookN.,
HallG. A.,
SharpeS.,
RudE. W.,
CranageM. P.1995; Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 69:5117–5123
Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope